Study of new drug plus standard care for large B-cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a new medicine called HDM2005 combined with standard treatments for adults with diffuse large B-cell lymphoma (DLBCL). It aims to see if the combination works better than standard care alone, and is for patients either newly diagnosed with a certain risk score or those who have already tried one or more prior treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have been diagnosed with diffuse large B-cell lymphoma (DLBCL).
- You must have at least one tumor that can be measured on a CT scan (at least 1.5 cm in a lymph node or 1 cm elsewhere).
- You have either not yet received any treatment for DLBCL (if you have a certain risk score) or have received at least one prior treatment (depending on the group).
- You do not have active lymphoma in the brain or spinal cord, and no history of certain lung or bleeding disorders.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called TRS005 combined with standard chemotherapy (cyclophosphamide, doxorubicin, and prednisone) for people who haven't yet been treated for a type of lymphoma called CD20-positive DLBCL. The goal is to see if adding TRS005 helps more people get better.
This trial tests a new drug called birelentinib combined with standard chemotherapy (R-CHOP) for people who have just been diagnosed with a type of lymphoma called DLBCL. The goal is to see if the combination works better than R-CHOP alone.
This trial tests a new drug, SHR-A1912, combined with standard chemotherapy (R-GemOx) for people with diffuse large B-cell lymphoma (DLBCL) that has returned or not improved after at least one prior treatment. It aims to see if the combination works better than chemotherapy alone.
This trial tests a new combination treatment (DZD8586) for people with diffuse large B-cell lymphoma (DLBCL). It looks at how well the drug works and how safe it is for both newly diagnosed patients and those whose cancer returned after initial treatment.
This trial tests a new combination of drugs (tafasitamab + lenalidomide + gemcitabine + oxaliplatin) against a standard combination (rituximab + gemcitabine + oxaliplatin) for people with DLBCL that has returned or stopped responding to prior therapy. The goal is to see if the new combination works better.
This trial is testing a new combination of drugs for people with a high-risk type of lymphoma called DLBCL who have not been treated before. It adds loncastuximab and roflumilast to the standard R-CHOP therapy to see if it works better at fighting the cancer.
Hear when a new Diffuse Large B Cell Lymphoma (DLBCL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.